We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing evorpacept (ALX148) as a foundational checkpoint immunotherapy

Evorpacept Mechanism of Action

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, evorpacept (ALX148), will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue evorpacept as a potentially critical component for future combination treatments in oncology.

Latest News updated at 20:46:14 UTC

Sep 16, 2021

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma

Sep 07, 2021

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

Aug 12, 2021

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights


ALX Oncology announced initiation of a Phase 1/2 investigator-sponsored trial of evorpacept (ALX148) in patients with indolent & aggressive non-Hodgkin lymphoma, which is being led by Dr. Paolo Strati at The University of Texas M.D. Anderson Cancer Center https://bit.ly/39gTaA4

ALX Oncology today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights: https://bit.ly/3xKKA6y

ALX Oncology today announced the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of #ALX148, a next generation #CD47 blocker, with KEYTRUDA® (pembrolizumab), for the treatment of patients with advanced #HNSCC: https://bit.ly/3yatVKO

Load More...

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, evorpacept, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.